Esanex, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.esanexpharma.com
Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)β’ Click on a phase to view related trials
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02973399
- Locations
- πΊπΈ
Weill Cornell Medical College, New York, New York, United States
πΊπΈWexner Medical Center, Ohio State University, Columbus, Ohio, United States
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Esanex Inc.
- Registration Number
- NCT02914327
- Locations
- πΊπΈ
Wexner Medical Center, Ohio State University, Columbus, Ohio, United States
Study of SNX-5422 in TP53 Null Cancers
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT02612285
- Locations
- πΊπΈ
HonorHealth Research Institute, Scottsdale, Arizona, United States
πΊπΈAugusta University, Augusta, Georgia, United States
πΊπΈKarmanos Cancer Institute, Detroit, Michigan, United States
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT02063958
- Locations
- πΊπΈ
Mayo Clinic, Scottsdale, Arizona, United States
πΊπΈStanford Medicine, Stanford, California, United States
πΊπΈGeorgetown University Medical Center, Washington, District of Columbia, United States
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Esanex Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01892046
- Locations
- πΊπΈ
Georgetown University Medical Center, Washington, D.C., District of Columbia, United States
πΊπΈGeorgia Regents University Cancer Center, Augusta, Georgia, United States
πΊπΈHackensack University Medical Center, Hackensack, New Jersey, United States
- Prev
- 1
- 2
- 3
- Next